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Abstract Phytoestrogens	  are	  plant	  compounds,	  which	  can	  be	  taken	  as	  an	  alternative	  to	  Hormone	  Replacement	  Therapy	  to	  treat	  symptoms	  of	  menopause.	  The	  proliferative	  effects	  of	  over	  the	  counter	  supplements	  containing	  two	  common	  phytoestrogens:	  red	  clover	  and	  soy,	  were	  tested	  on	  T47D-­‐Kbluc	  cells	  using	  MTT	  assays.	  We	  observed	  differences	  in	  proliferation	  between	  the	  supplements	  tested.	  We	  have	  identified	  unique	  common	  peaks	  between	  supplement	  chromatograms	  and	  have	  discussed	  their	  potential	  effects	  on	  cell	  proliferation.	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Background Breast	  cancer	  is	  one	  of	  the	  most	  common	  and	  deadly	  forms	  of	  cancer	  in	  the	  United	  States.	  The	  disease	  is	  expected	  to	  develop	  in	  1	  out	  of	  every	  8	  women	  in	  the	  U.S.	  (Breastcancer.org,	  2014),	  and	  kills	  more	  women	  than	  all	  other	  cancers	  excluding	  lung	  cancer.	  Hormone	  Replacement	  Therapy	  (HRT),	  a	  process	  that	  introduces	  estrogen	  into	  a	  patient	  is	  often	  use	  to	  treat	  symptoms	  of	  menopause	  (Holli	  et.	  al.,	  1998).	  Recent	  studies	  about	  the	  effects	  of	  HRT	  on	  breast	  cancer	  have	  raised	  concerns	  that	  HRT	  may	  increase	  the	  patients’	  risk	  for	  breast	  cancer	  (Katalinic	  et.	  al.,	  2008).	  This	  study	  hopes	  to	  find	  other	  methods	  of	  successfully	  treating	  breast	  cancer	  by	  using	  phytoestrogens,	  or	  estrogen	  derived	  from	  plants.	  	  
Hormones and Estrogen Activity 
Introduction to Hormones Hormones	  are	  a	  class	  of	  circulatory	  signaling	  molecules	  that	  play	  an	  important	  role	  in	   many	   physiological	   functions.	   They	   are	   comprised	   of	   three	   classes:	   amine	  hormones,	   peptide	   hormones,	   or	   steroid	   hormones.	   While	   amine	   hormones	   are	  created	  via	  the	  typical	  formation	  of	  amino	  acids,	  peptide	  hormones	  are	  synthesized	  by	   the	   formation	   of	   short	   chains	   created	   by	   peptide	   bonds	   between	  many	   amino	  acids	  (Taylor	  et.	  al.,	  2000).	  Steroid	  hormones,	  otherwise	  known	  as	  steroids,	  are	  not	  amino-­‐acid	   based	   and	   don't	   have	   to	   bind	   to	   a	   receptor	   on	   the	   cellular	   surface	   to	  enter	  the	  cell	  (Klinge	  et.	  al.,	  2008,	  Figure	  5A).	  This	  makes	  the	  regulation	  of	  steroid	  hormones	  all	  that	  more	  important,	  as	  the	  lipid-­‐based	  family	  of	  molecules	  can	  freely	  diffuse	  across	  the	  cell	  membrane.	  
Normal Estrogen Receptor Activity Estrogen	  Receptors	  are	  responsible	  for	  regulating	  transcriptional	  activity	  (Simpson	  et.	  al.,	  2001).	  	  After	  an	  estrogen	  receptor	  binds	  with	  an	  estrogen	  molecule	  that	  elicits	  an	  agonistic	  response,	  coactivators	  dimerize	  with	  two	  ligand-­‐bound	  complexes	  and	  bind	   to	   Estrogen	   Response	   Elements	   (EREs),	   which	   are	   types	   of	   DNA	   sequences	  activated	   in	   the	   presence	   of	   estrogen	   (Kimball,	   2011).	   These	   hormone	   response	  elements	   are	   located	   near	   the	   promoter	   that	   activates	   transcription	   when	   bound	  (Hyder	   et.	   al.,	   2000).	   These	   regions	   can	   only	   be	   activated	   in	   the	   presence	   of	   an	  estrogen	   molecule	   that	   elicits	   an	   agonistic	   response,	   as	   transcription	   is	   naturally	  "turned	   off"	   (Hyder	   et.	   al.,	   2000).	   Estrogen	   molecules	   can	   elicit	   a	   full	   range	   of	  responses,	   from	   fully	  agonistic	   (completely	  activates	   the	   transcriptional	   region)	   to	  fully	   antagonistic	   (completely	   de-­‐activates	   the	   transcriptional	   region)	   and	  everything	   in	   between	   (activates	   or	   de-­‐activates	   the	   transcriptional	   region	  depending	   on	   cellular	   conditions)	   (Stovall	   et.	   al.,	   2008).	   A	   decrease	   in	   steroid	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concentrations	  brought	  on	  by	  biological	  processes	  such	  as	  menopause	  (Simpson	  et.	  al.,	  2001)	  can	  make	  it	  difficult	  for	  proper	  metabolic	  activity.	  
Estrogen-Deficient Receptor Activity Individuals	   that	   suffer	   from	   estrogen-­‐deficient	   conditions	   like	   menopause	   force	  their	  estrogen	  receptors	  to	  adjust	  to	  a	  lower	  estrogen	  concentration.	  This	  presents	  two	  problems.	  First,	  an	  inability	  of	  ERs	  to	  adjust	  to	  low	  levels	  of	  estrogen	  can	  lead	  to	  a	  decrease	   in	   transcriptional	  activity	   that	  often	  manifests	   itself	   through	  symptoms	  such	   as	   bone	   loss	   (Riggs	   et.	   al.,	   1998).	   Second,	   individuals	   that	   have	   adjusted	   to	  lower	   levels	   of	   estrogen	   show	   increasing	   sensitivity	   to	   hormones	   (Riggs	   et.	   al.,	  1998).	  It's	  been	  noted	  that	  cancer	  cells	  express	  estrogen-­‐sensitive	  markers,	  and	  the	  formation	  of	  estrogen-­‐sensitive	  cells	  are	  theorized	  to	  lead	  to	  cancer	  cells	  (Diel	  et.	  al.,	  2002)	   Some	   treatments	   for	   those	  with	   low	   steroid	   hormone	   concentrations	   have	  already	   been	   tested,	   but	   with	   mixed	   results.	   Hormone	   Replacement	   Therapy	   can	  treat	  some	  menopausal	  symptoms	  by	  increasing	  the	  amount	  of	  circulating	  estrogen	  in	  an	  individual,	  but	  has	  also	  been	  shown	  to	  put	  recipients	  at	  risk	  for	  cancer	  (Cui	  et.	  al.,	  2014).	  
Menopause and Hormone Replacement Therapy 
Menopause Definition Menopause	  is	  defined	  as	  the	  end	  of	  menstruation	  due	  to	  reduced	  secretion	  of	  estrogen	  and	  progesterone	  (Nelson,	  2008).	  	  There	  is	  a	  transitional	  period	  of	  roughly	  4-­‐5	  years	  that	  is	  characterized	  by	  more	  irregular	  menstrual	  cycles,	  but	  women’s	  ages	  at	  the	  time	  of	  their	  final	  cycle	  vary	  (Nelson,	  2008).	  	  Menopause	  can	  be	  accompanied	  by	  unpleasant	  symptoms,	  the	  most	  common	  being	  “hot	  flashes”,	  and	  “night	  sweats”.	  
Symptoms and Treatment There	  are	  many	  symptoms	  commonly	  associated	  with	  menopause.	  Symptoms	  can	  include,	  but	  are	  not	  limited	  to,	  vasomotor	  episodes	  (“Hot	  Flashes”),	  vaginal	  dryness,	  incontinence,	  mood	  changes,	  and	  reduced	  libido	  (Nelson,	  2008).	  Vasomotor	  episodes	  are	  one	  of	  the	  most	  commonly	  reported	  symptoms	  of	  menopause.	  They	  are	  characterized	  by	  a	  warming	  feeling	  in	  the	  face	  and	  chest,	  and	  often	  associated	  with	  perspiration,	  palpitations,	  and	  a	  feeling	  of	  anxiety	  (Nelson	  2008).	  	  Patients	  report	  that	  vasomotor	  episodes	  affect	  sleep,	  which	  can	  lead	  to	  a	  decrease	  in	  overall	  health	  in	  the	  long-­‐term.	  These	  episodes	  can	  occur	  for	  up	  to	  5	  years	  post-­‐menopause,	  and	  are	  often	  more	  severe	  in	  patients	  who	  have	  surgically	  induced	  menopause	  	  (Bachmann,	  1999).	  Patients	  who	  have	  severe	  symptoms	  often	  seek	  treatment,	  to	  preserve	  quality	  of	  life.	  In	  addition	  to	  the	  commonly	  reported	  symptoms,	  menopause	  can	  also	  cause	  more	  serious	  problems.	  These	  more	  severe	  conditions	  include	  heart	  disease,	  osteoporosis,	  and	  cancer	  (Watkins,	  2007).	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  Osteoporosis	  is	  common	  in	  menopausal	  and	  post-­‐menopausal	  women	  because	  of	  the	  reduction	  of	  hormone	  production	  in	  the	  ovaries	  (Lindsay,	  1996).	  The	  reduced	  amount	  of	  estrogen	  causes	  an	  increase	  in	  reabsorption	  of	  skeletal	  mass,	  and	  leads	  to	  an	  increase	  in	  fractures	  from	  minor	  accidents	  or	  falls	  (Lindsay,	  1996).	  These	  effects	  can	  be	  offset	  by	  using	  a	  replacement	  for	  estrogen,	  or	  a	  “bone	  specific	  agent”	  to	  reduce	  the	  reabsorption	  of	  the	  skeletal	  mass	  (Lindsay,	  1996).	  	  Physicians	  and	  researchers	  have	  developed	  several	  scales	  to	  gage	  the	  severity	  of	  symptoms	  in	  a	  specific	  patient	  relative	  to	  a	  larger	  group,	  and	  advise	  treatment	  plans.	  The	  menopause-­‐specific	  quality	  of	  life	  questionnaire,	  Green	  climacteric	  scale,	  and	  Blat-­‐Kupperman	  index	  are	  some	  of	  the	  most	  commonly	  used	  and	  referenced	  .	  Most	  of	  these	  scales	  and	  scores	  rely	  heavily	  on	  self-­‐reporting	  of	  symptoms	  (Nelson,	  2008).	  Self-­‐reporting	  is	  not	  a	  reliable	  source	  for	  physicians	  to	  use	  to	  make	  a	  diagnosis,	  or	  to	  prescribe	  treatment	  (Nelson,	  2008).	  	  In	  the	  2008	  US	  Census	  the	  average	  life	  expectancy	  for	  females	  in	  the	  United	  States	  was	  80.5	  years	  (US	  Census	  Bureau,	  2012).	  This	  would	  give	  a	  woman	  a	  minimum	  of	  30	  years	  of	  postmenopausal	  life	  (assuming	  that	  their	  last	  menstrual	  period	  occurred	  at	  the	  age	  of	  60).	  The	  most	  common	  treatment	  for	  menopause	  is	  Hormone	  Replacement	  Therapy	  (HRT).	  Some	  “non-­‐prescribed	  therapies”	  including	  red	  clover,	  soy,	  and	  black	  cohosh	  herbal	  supplements	  are	  commonly	  used,	  but	  there	  is	  not	  much	  data	  to	  support	  or	  refute	  their	  success	  (Nelson,	  2008).	  There	  are	  more	  varied	  treatment	  methods	  that	  are	  shown	  to	  be	  no	  different	  than	  placebo	  when	  used	  to	  treat	  menopausal	  symptoms	  including	  magnets,	  aerobics,	  Chinese	  herbs,	  and	  “reflexology”	  (Nelson,	  2008).	  
History of Hormone Replacement Therapy Hormone	  Replacement	  Therapy	  (HRT)	  is	  a	  medical	  procedure	  where	  synthetic	  hormones	  are	  used	  to	  prevent	  or	  treat	  symptoms	  of	  a	  specific	  medical	  condition.	  Historically,	  HRT	  was	  prescribed	  as	  a	  preventative	  measure	  against	  conditions	  including	  osteoporosis,	  heart	  disease	  and	  other	  signs	  of	  aging	  especially	  in	  women,	  however	  in	  many	  cases	  the	  risks	  outweigh	  the	  benefits	  (Watkins,	  2007).	  Long	  term	  HRT	  is	  most	  commonly	  prescribed	  for	  women	  who	  have	  entered	  menopause.	  HRT	  is	  also	  commonly	  used	  in	  male-­‐to-­‐female	  transitioning	  of	  transgendered	  individuals,	  and	  for	  alleviating	  symptoms	  of	  genetic	  conditions	  such	  as	  Turner	  Syndrome	  (Bolar,	  2008).	  
Estrogen and Estrogen Receptors Estrogen	  is	  the	  main	  female	  hormone	  used	  in	  menopausal	  HRT.	  	  It	  gained	  immense	  popularity	  in	  the	  1960s	  as	  a	  way	  to	  alleviate	  the	  symptoms	  of	  menopause,	  however	  in	  1975	  it	  was	  discovered	  that	  the	  risk	  of	  endometrial	  cancer	  was	  increased	  (Watkins,	  2007).	  Estrogen	  regained	  some	  popularity	  in	  the	  1980s	  after	  the	  hormone	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progestin	  was	  added	  in	  combination,	  however	  estrogen-­‐progestin	  therapy	  leaves	  users	  with	  increased	  risk	  of	  breast	  cancer,	  blood	  clots,	  and	  stroke	  (Watkins,	  2007).	  	  There	  are	  two	  subtypes	  of	  human	  estrogen	  receptors,	  Estrogen	  Receptor	  α	  (ERα)	  and	  Estrogen	  Receptor	  β	  (ERβ)	  (Morito,	  2001).	  Both	  estrogen	  receptors	  alpha	  and	  beta	  are	  co-­‐expressed	  in	  about	  half	  of	  breast	  cancer	  cases	  (Lattrich,	  2014).	  The	  estrogen	  receptors	  are	  similar	  but	  differ	  in	  their	  C-­‐terminal	  ligand-­‐binding	  domain	  and	  in	  the	  N-­‐terminal	  transactivation	  domain	  (Morito,	  2001).	  The	  roles	  of	  ER	  alpha	  and	  ER	  beta	  in	  breast	  cancer	  pathogenesis	  are	  becoming	  increasingly	  clearer	  due	  to	  several	  clinical	  and	  in	  vitro	  studies	  (Rizza,	  2014).	  The	  two	  estrogen	  receptors	  are	  responsible	  for	  opposite	  roles	  in	  regulating	  cell	  proliferation	  (Powell,	  2012).	  
ERα ERα	  is	  a	  nuclear	  hormone	  receptor	  and	  transcription	  factor	  that	  helps	  regulate	  gene	  expression	  and	  is	  involved	  in	  cell	  proliferation	  (Rizza,	  2014).	  It	  has	  also	  been	  found	  that	  without	  the	  alpha-­‐receptor	  the	  mammary	  ducts	  become	  truncated	  and	  do	  not	  fully	  develop.	  ERα	  is	  involved	  in	  cancer-­‐promoting	  effects	  in	  response	  to	  estrogen	  and	  has	  been	  shown	  to	  be	  an	  effective	  therapeutic	  target	  for	  years	  (Powell,	  2012).	  	  The	  alpha-­‐receptor	  has	  been	  linked	  to	  some	  of	  the	  carcinogenic	  effects	  of	  estrogen	  in	  breast	  (Powell,	  2012).	  
ERβ Like	  the	  alpha-­‐receptor	  the	  beta-­‐receptor	  is	  a	  nuclear	  hormone	  receptor	  and	  a	  transcription	  factor	  that	  helps	  regulate	  gene	  expression	  (Rizza,	  2014).	  Unlike	  the	  alpha-­‐receptor	  that	  is	  believed	  to	  play	  a	  role	  in	  cell	  proliferation,	  the	  beta-­‐receptor	  is	  believed	  to	  be	  responsible	  for	  the	  inhibition	  of	  cell	  proliferation	  (Morito,	  2001).	  This	  was	  determined	  after	  many	  studies	  and	  experiments,	  produced	  results	  supporting	  the	  hypothesis	  of	  inhibiting	  cell	  proliferation	  (Powell,	  2012).	  
Phytoestrogens Available	  knowledge	  suggests	  phytoestrogens	  affect	  numerous	  processes	  related	  to	  reproduction,	  bone	  remodeling,	  skin,	  cardiovascular,	  nervous,	  immune	  systems	  and	  metabolism.	  This	  potentially	  leads	  to	  useful	  prevention	  of	  diseases	  (Alexander,	  2014).	  Phytoestrogens	  are	  non-­‐steroidal	  estrogens	  that	  are	  located	  found	  in	  many	  species	  of	  the	  plant	  kingdom.	  Phytoestrogens	  are	  similar	  in	  chemical	  structure	  to	  mammalian	  estrogen,	  estradiol.	  This	  results	  in	  their	  ability	  to	  bind	  to	  estrogen	  receptors	  alpha	  and	  beta	  with	  a	  preference	  for	  the	  beta	  receptor	  (Younes	  and	  Honma,	  2011).	  After	  binding	  to	  the	  receptor	  in	  the	  cytoplasm,	  they	  are	  able	  to	  move	  from	  the	  cytoplasm	  to	  the	  nucleus	  of	  the	  cell	  where	  they	  bind	  estrogen	  response	  elements	  and	  affect	  transcription,	  resulting	  in	  control	  of	  expression	  of	  target	  genes	  (Sirotkin,	  2014).	  Estrogen	  receptor	  alphas	  are	  considered	  as	  promoters	  of	  cell	  proliferation	  and	  estrogen	  receptor	  beta	  promote	  cellular	  apoptosis	  (Rietjens	  et	  al.,	  2013).	  	  According	  to	  their	  chemical	  structure	  and	  biosynthesis	  pathways,	  phytoestrogens	  are	  divided	  into	  flavonoids,	  coumestan,	  lignans,	  stilbenoids,	  and	  miscellaneous	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classes.	  This	  study	  will	  focus	  on	  flavonoids	  because	  of	  their	  widespread	  presence	  in	  over	  the	  counter	  supplements	  that	  advertise	  relief	  of	  menopause	  symptoms.	  Flavanoids	  are	  further	  divided	  into	  flavones,	  flavonols,	  flavanones,	  and	  isoflavonoids	  (Alexander,	  2014).	  
Coumestan Coumestan	  is	  a	  derivative	  of	  simple	  isoflavonoids	  and	  is	  generally	  found	  in	  alfalfa	  and	  clover.	  Because	  of	  its	  availability	  in	  mostly	  alfalfa,	  it	  is	  more	  linked	  to	  veterinary	  science	  than	  human	  nutrition	  (Dixon,	  2004).	  It	  has	  strong	  estrogen-­‐like	  activity	  and	  higher	  binding	  affinity	  for	  the	  estrogen	  receptor	  than	  genistein	  (Tinwell	  et	  al.,	  2000).	  
Lignans Lignans	  are	  a	  diverse	  class	  of	  phenylpropanooid	  dimers	  and	  oligomers,	  which	  are	  a	  family	  of	  organic	  compounds	  that	  are	  synthesized	  by	  plants	  from	  phenylalanine.	  They	  are	  generally	  found	  in	  high	  amounts	  in	  flaxseed,	  whole	  grain	  bread,	  vegetables,	  and	  tea	  (Cornwell	  et	  al.,	  2004).	  Because	  of	  their	  availability	  in	  cereals	  and	  grains,	  they	  account	  for	  the	  majority	  of	  total	  phytoestrogen	  exposure	  (Fletcher,	  2003).	  Evidence	  of	  health	  benefits	  come	  from	  epidemiological	  and	  intervention	  studies.	  In	  a	  study	  done	  by	  Peterson	  et	  al.	  (2010),	  intervention	  studies	  using	  flaxseed	  lignan	  supplements	  and	  sesamin	  supplements	  showed	  beneficial	  associations	  with	  C-­‐reactive	  protein	  and	  meta-­‐analysis	  which	  suggested	  a	  lowering	  effect	  on	  plasma	  total	  and	  low-­‐density	  lipoprotein	  cholesterol,	  as	  well	  as,	  possible	  lipid	  and	  blood	  pressure	  lowering.	  Observational	  epidemiological	  studies	  showed	  some	  decreased	  risk	  of	  cardiovascular	  disease	  showing	  a	  promising	  association	  but	  not	  well	  established	  (Peterson	  et	  al.,	  2010).Benefits	  are	  equal	  with	  those	  of	  isoflavones	  that	  are	  thought	  to	  be	  wide,	  ranging	  from	  prevention	  of	  cardiovascular	  disease	  and	  cancer,	  to	  cognitive	  ability	  (Salter	  et	  al.,	  2012).	  
Stilbenoids Stilbenoids,	  like	  isoflavonoids,	  are	  produced	  through	  the	  phenylpropanoid-­‐acetate	  pathway.	  The	  main	  sources	  of	  stilbenoids	  are	  from	  resveratrol	  from	  red	  wine	  and	  peanuts.	  However,	  only	  the	  trans	  form	  of	  resveratrol	  has	  been	  shown	  to	  be	  estrogenic.	  Resveratrol	  has	  shown	  agonistic	  and	  antagonistic	  activity	  in	  MCF-­‐7	  cells	  and	  CHO-­‐K1	  cells	  transfected	  with	  human	  estrogen	  receptors	  (Cornwell	  et	  al.,	  2004).	  Like	  other	  phytoestrogens,	  principle	  health	  benefits	  of	  resveratrol	  ingestion	  are	  prevention	  of	  cardiovascular	  disease	  and	  cancer	  (Salter	  et	  al.,	  2012).	  
Flavonoids Isoflavonoids	  are	  formed	  by	  a	  branch	  of	  the	  flavonoid	  biosynthetic	  pathway.	  They	  originate	  from	  naringenin	  in	  genistein	  biosynthesis	  and	  liquirtigenin	  in	  diadzein	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biosynthesis	  both	  of	  which	  are	  flavonoid	  intermediates	  (Dixon,	  2004).	  	  Genestein,	  one	  of	  the	  common	  isoflavonoids,	  has	  a	  wide	  variety	  of	  pharmacological	  effects	  in	  animal	  cells,	  including	  tyrosine	  kinase	  inhibition,	  chemoprevention	  of	  breast	  and	  prostate	  cancers,	  cardiovascular	  disease	  and	  post-­‐menopausal	  ailment	  relief	  (Dixon	  et	  al.,	  2002).	  For	  example,	  a	  study	  done	  in	  perimenopausal	  women	  showed	  that	  soy	  isoflavones	  attenuated	  bone	  loss	  from	  the	  lumbar	  spine	  in	  patients.	  This	  was	  further	  speculated	  that	  the	  isoflavones	  rather	  than	  the	  soy	  protein	  attributed	  to	  this	  effect	  (Alekel	  et	  al.,	  2000).	  Genistein	  shares	  structural	  features	  with	  estradiol-­‐17β,	  specifically,	  in	  the	  area	  that	  confers	  the	  ability	  to	  bind	  estrogen	  receptors	  and	  secondary	  hormone	  binding	  proteins.	  This	  allows	  genistein	  to	  have	  both	  estrogenic	  and	  anti-­‐estrogenic	  activity	  (Dixon	  et	  al.,	  2002).	  This	  is	  due	  to	  the	  activation	  and	  inhibition	  of	  the	  estrogen	  receptor	  types,	  which	  can	  induce	  or	  inhibit	  estrogen	  signaling	  (Mueller	  et	  al.,	  2004).	  The	  anti-­‐estrogenic	  activity	  is	  due	  to	  competition	  binding	  between	  the	  isoflavonoid	  and	  estradiol.	  This	  is	  shown	  in	  an	  example	  by	  tamoxifen,	  which	  is	  a	  chemo	  preventive	  agent	  in	  women	  with	  high	  risk	  of	  breast	  cancer.	  Tamoxifen	  is	  structurally	  similar	  to	  genistein	  and	  thus	  competes	  with	  it	  (Dixon	  et	  al.,	  2002).	  	  	  
The Food and Drug Administration 
History The	  Food	  and	  Drug	  Administration	  (FDA)	  began	  to	  function	  as	  it	  is	  known	  today	  in	  1906	  after	  the	  passage	  of	  the	  Pure	  Food	  and	  Drugs	  Act.	  	  The	  FDA	  is	  responsible	  for	  the	  analysis	  and	  regulation	  through	  safety	  standards	  of	  human	  and	  veterinary	  drugs,	  the	  United	  States	  food	  supply,	  cosmetics,	  etc.	  The	  FDA	  is	  also	  charged	  with	  pressing	  for	  innovation	  in	  providing	  safe,	  affordable,	  and	  effective	  medicine	  to	  the	  public.	  
Over the Counter Drugs vs. Dietary Supplements The	  FDA’s	  classifications	  and	  regulatory	  procedures	  for	  Over	  the	  Counter	  (OTC)	  Drugs	  and	  Dietary	  supplements	  are	  different.	  These	  differences	  are	  part	  of	  what	  makes	  the	  classification	  of	  a	  product	  important	  to	  companies,	  more	  lax	  regulations	  can	  allow	  subpar	  products	  to	  pass	  under	  the	  radar.	  An	  OTC	  Drug	  is	  one	  that	  has	  been	  proven	  to	  be	  safe	  to	  use	  without	  professional	  supervision.	  OTC	  drugs	  can	  be	  approved	  by	  the	  FDA	  by	  the	  submission	  of	  an	  application.	  More	  commonly	  they	  are	  marketed	  by	  following	  an	  “OTC	  drug	  monograph”.	  An	  OTC	  drug	  monograph	  states	  appropriate	  usage	  and	  dosing	  for	  the	  specific	  ingredients	  used	  in	  a	  product.	  OTC	  drug	  monographs	  allow	  a	  product	  to	  bypass	  FDA	  review	  and	  go	  straight	  to	  the	  market	  (FDA,	  2014).	  According	  to	  the	  Center	  for	  Drug	  Evaluation	  and	  Research	  (CDER)	  the	  required	  information	  on	  OTC	  Drug	  Labels	  is	  as	  follows:	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v Title	  (Drug	  Facts	  or	  Drug	  Facts	  (continued))	  





v Other	  Information	  
v Inactive	  Ingredients	  




v Amino	  acids	  
v Other	  substances	  found	  in	  the	  human	  diet	  Dietary	  supplements	  may	  not	  be	  advertised	  as	  conventional	  foods,	  and	  in	  place	  of	  “Nutritional	  Facts”	  labels	  must	  have	  a	  “Supplement	  Facts”	  label.	  Additionally,	  because	  supplements	  are	  a	  type	  of	  “food”	  they	  are	  not	  required	  to	  be	  approved	  by	  the	  FDA	  before	  being	  brought	  to	  market.	  Instead	  it	  is	  the	  responsibility	  of	  the	  producer	  to	  ensure	  that	  the	  product	  is	  safe,	  contains	  no	  misleading	  or	  false	  claims,	  and	  otherwise	  follows	  all	  FDA	  standards	  for	  a	  food	  product.	  (FDA,	  2014).	  
What this means for Phytoestrogens Most	  common	  phytoestrogen	  supplements	  like	  Promensil	  are	  sold	  as	  dietary	  supplements	  rather	  than	  OTC	  drugs	  regardless	  of	  how	  they	  are	  being	  used.	  Due	  to	  the	  more	  lax	  regulatory	  standards	  set	  for	  dietary	  supplements	  these	  products	  can	  be	  brought	  to	  market	  and	  sold	  until	  such	  a	  time	  that	  the	  product	  is	  shown	  to	  be	  unsafe	  or	  it	  is	  reclassified	  as	  a	  drug,	  and	  held	  to	  those	  regulatory	  standards.	  Without	  the	  strict	  regulatory	  standards,	  there	  is	  a	  huge	  variety	  in	  the	  types	  of	  phytoestrogen	  supplements	  available	  on	  the	  market,	  and	  the	  effect	  or	  lack	  of	  effect	  of	  the	  products	  on	  consumers	  could	  be	  wildly	  variable	  depending	  on	  the	  brand,	  concentration	  of	  “active	  ingredient”,	  delivery	  system	  and	  many	  other	  variables.	  
T47D-KBluc Cell Line 
Origin T47D-­‐KBluc	  cells	  are	  a	  line	  of	  human	  breast	  cancer	  cells	  that	  luminesce	  under	  exposure	  to	  estrogen	  (Wilson	  et.	  al.,	  2004).	  In	  order	  to	  form	  the	  T47D-­‐KBluc	  line,	  T47D	  cells	  are	  infected	  with	  estrogen-­‐responsive	  luciferase	  reporter	  gene	  constructs.	  	  After	  estrogen	  molecules	  bind	  to	  estrogen	  receptors,	  two	  of	  the	  ligand-­‐
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bound	  receptor	  complexes	  dimerize	  and	  bind	  to	  EREs.	  These	  EREs	  are	  DNA	  sequences	  upstream	  from	  a	  TATA	  box	  that	  regulates	  expression	  of	  the	  luciferase	  reporter	  gene	  (Wilson	  et.	  al.,	  2004).	  A	  luciferase	  enzyme	  assay	  can	  then	  be	  used	  to	  quantify	  the	  luminescence	  of	  the	  reporter	  gene	  brought	  on	  by	  estrogen	  exposure.	  After	  the	  cells	  have	  been	  plated	  and	  exposed	  to	  the	  proper	  assay	  conditions,	  they	  luminesce	  almost	  instantly	  (Biotium,	  2014).	  The	  lack	  of	  background	  luminescence	  means	  that	  the	  measured	  cell	  luminescence	  can	  be	  fully	  attributed	  to	  luciferase	  expression	  (Biotium,	  2014).	  Estrogen	  has	  a	  strong	  effect	  on	  the	  activity	  of	  the	  luciferase	  reporter	  gene,	  as	  increasing	  concentrations	  of	  17β-­‐Estradiol	  from	  1x10-­‐4	  nM	  to	  0.1	  nM	  have	  been	  shown	  to	  increase	  the	  fold	  induction	  of	  the	  reporter	  gene	  by	  almost	  10-­‐fold	  (Wilson	  et.	  al.,	  2004,	  Figure	  2A).	  
Effects of Soy Supplements on Cancer Cell Proliferation Many	  dietary	  supplements	  use	  soy	  as	  an	  ingredient.	  Supplements	  containing	  soy	  have	  been	  shown	  to	  reduce	  proliferation	  of	  estrogen-­‐dependent	  cancer	  in	  some	  studies	  (Kang	  et.	  al.	  2009),	  but	  have	  resulted	  in	  no	  change	  in	  cancer	  proliferation	  for	  other	  studies	  (Shike	  et.	  al.,	  2014)	  (Moss	  et.	  al.,	  2014).	  The	  most	  common	  phytoestrogens	  found	  in	  soy	  supplements	  are	  genistein	  and	  daidzein.	  Genistein	  use	  has	  shown	  an	  increase	  in	  cancer	  proliferation	  when	  using	  large	  doses	  (Kuiper	  et.	  al.,	  1997),	  but	  may	  still	  cause	  a	  decrease	  in	  proliferation	  at	  lower	  concentrations	  (Setchell	  et.	  al.,	  2001).	  Daidzein	  has	  been	  shown	  to	  reduce	  cancer	  proliferation	  (Lepri	  et.	  al.,	  2014).	  The	  lack	  of	  definitive	  results	  on	  the	  effects	  phytoestrogens	  have	  on	  estrogen-­‐dependent	  cancer	  are	  concerning	  due	  to	  the	  possibility	  that	  some	  components	  of	  the	  supplements	  could	  actually	  be	  harmful.	  
Effects of Red Clover Supplements on Cancer Cell Proliferation Red	  clover	  is	  another	  plant	  commonly	  found	  in	  dietary	  supplements.	  Supplements	  containing	  red	  clover	  have	  caused	  decreases	  in	  cancer	  cell	  proliferation	  (Caron,	  2007),	  as	  well	  as	  increased	  proliferation	  (Chen	  et.	  al.,	  2015).	  Daidzein	  has	  been	  shown	  to	  reduce	  cancer	  proliferation	  at	  the	  right	  concentration.	  	  Biochanin	  A	  has	  been	  shown	  to	  reduce	  proliferation	  in	  a	  number	  of	  studies	  (Johnson,	  2010),	  but	  has	  also	  been	  shown	  to	  promote	  proliferation	  as	  well.	  Although	  treatment	  of	  estrogen-­‐dependent	  cancer	  with	  phytoestrogens	  has	  led	  to	  mixed	  results,	  more	  research	  should	  be	  done	  on	  the	  subject	  as	  these	  supplements	  may	  provide	  a	  safer	  altenrative	  to	  HRT	  if	  they	  have	  inhibitory	  properties	  such	  as	  with	  diadzen	  and	  biochannin	  A.  




T47D-KBluc Cell Line Cells	  were	  maintained	  at	  37	  degrees	  Celsius	  in	  DMEM	  +	  10%	  Fetal	  Bovine	  Serum	  +	  	  1%	  PenStrep	  +	  Glutamine	  media.	  T25	  flasks	  were	  maintained	  in	  5mL,	  and	  T75	  flasks	  were	  maintained	  in	  10mL	  of	  media.	  Cells	  were	  fed	  new	  media	  as	  needed,	  and	  split	  as	  they	  approached	  approximately	  85-­‐90%	  confluence.	  
Extraction Solvent	  extractions	  were	  performed	  on	  the	  varying	  supplements,	  and	  then	  refluxed	  according	  to	  the	  procedures	  outlined	  in	  Setchell	  et.	  al.	  (2001).	  Due	  to	  the	  variation	  of	  phytoestrogen	  concentration	  across	  supplements	  different	  amounts	  of	  the	  supplements	  were	  used	  in	  the	  extractions,	  in	  order	  to	  get	  similar	  concentrations	  of	  phytoestrogens	  across	  all	  supplements.	  A	  given	  supplement	  was	  added	  to	  a	  250-­‐mL	  round-­‐bottom	  flask.	  80	  mL	  of	  80%	  methanol	  were	  added	  to	  the	  round-­‐bottom	  flask.	  After	  the	  solution	  was	  mixed,	  the	  flask	  	  was	  attached	  to	  a	  reflux	  condenser.	  The	  solution	  was	  refluxed	  for	  1	  hour	  in	  a	  65°C	  water	  bath.	  The	  solution	  was	  then	  purified	  using	  a	  syringe	  filter	  and	  stored	  at	  -­‐20°C	  
Supplement Extraction 
Spring	  Valley	  Soy	  Isoflavone	  Three	  80mg	  tablets	  underwent	  solvent	  extraction	  after	  being	  crushed	  in	  a	  sterile	  mortar	  and	  pestle.	  This	  represents	  1.5	  serving	  sizes	  as	  indicated	  on	  the	  product	  packaging.	  As	  the	  first	  supplement	  extracted,	  using	  one	  serving	  size	  was	  decided	  after	  this	  extraction	  had	  been	  completed.	  
Promensil	  One	  80mg	  tablet	  underwent	  solvent	  extraction	  after	  being	  crushed	  in	  a	  sterile	  mortar	  and	  pestle.This	  represents	  one	  serving	  size	  as	  indicated	  on	  the	  product	  packaging.	  
Wild	  Harvest	  Red	  Clover	  Extraction	  was	  performed	  using	  three	  350mg	  capsules.	  This	  represents	  one	  serving	  size	  as	  indicated	  on	  the	  product	  packaging.	  
Piping	  Rock	  Soy	  Isoflavone	  Extraction	  was	  performed	  using	  three	  650mg	  capsules.	  This	  represents	  one	  serving	  size	  as	  indicated	  on	  the	  product	  packaging.	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Red	  Clover	  Plant	  1	  gram	  of	  dried	  red	  clover	  flowers	  were	  weighed	  and	  crushed	  in	  a	  sterile	  mortar	  and	  pestle.	  The	  crushed	  flowers	  were	  then	  extracted.	  	  
High Performance Liquid Chromatography Samples	  were	  injected	  onto	  a	  reverse	  phase	  C18	  250	  X	  4.6	  mm	  column	  in	  20	  μL	  and	  100	  μL	  volumes.	  Following	  the	  HPLC	  procedure	  outlined	  in	  Caron	  (2007),	  the	  column	  was	  washed	  with	  a	  solution	  of	  10	  mM	  ammonium	  acetate	  and	  0.1%	  of	  trifluoroacetic	  acid	  for	  two	  minutes.	  The	  column	  was	  then	  washed	  with	  a	  linear	  gradient	  of	  10	  mM	  ammonium	  acetate-­‐0.1%	  TFA	  and	  100%	  acetonitrile	  for	  the	  next	  22	  minutes.	  The	  percentage	  of	  the	  wash	  comprised	  of	  10	  mM	  ammonium	  acetate-­‐0.1%	  TFA	  for	  this	  time	  period	  varied	  between	  100%	  -­‐	  50%,	  while	  the	  percentage	  of	  the	  wash	  comprised	  of	  100%	  acetonitrile	  varied	  between	  0%	  -­‐	  50	  %	  during	  this	  time	  period.	  The	  column	  was	  then	  washed	  with	  a	  solution	  containing	  50%	  ammonium	  acetate-­‐TFA	  and	  50%	  acetonitrile	  for	  5	  minutes.	  Finally,	  the	  column	  was	  washed	  with	  100%	  ammonium	  acetate-­‐TFA	  for	  6	  minutes.	  The	  absorbance	  of	  the	  samples	  was	  measured	  at	  260	  nm,	  and	  used	  to	  generate	  a	  chromatogram.	  The	  peaks	  generated	  by	  the	  chromatogram	  show	  the	  absorbance	  (in	  mAu's,	  or	  micro	  absorbance	  units)	  of	  the	  sample	  at	  a	  given	  time	  during	  its	  run.	  The	  chromatograms	  of	  the	  Spring	  Valley,	  Promensil,	  Wild	  Harvest,	  and	  Piping	  Rock	  samples	  were	  compared	  to	  the	  chromatograms	  of	  genistein,	  daidzein,	  and	  biochanin-­‐A	  to	  match	  the	  	  	  Elution	  times	  	  of	  the	  known	  phytoestrogens	  with	  peaks	  found	  in	  	  the	  phytoestrogen	  supplements.	  
	  
Serial Dilution Five	  ten-­‐fold	  dilutions	  were	  created	  from	  the	  red	  clover	  plant	  extraction	  and	  each	  supplement	  extraction.	  The	  dilutions	  were	  made	  by	  mixing	  100	  uL	  of	  the	  stock	  extraction	  with	  900	  uL	  of	  90%	  methanol	  in	  a	  1.5	  mL	  microfuge	  tube.	  The	  dilution	  was	  vortexed	  thus	  becoming	  the	  first	  10	  fold	  dilution	  (10-­‐1)	  in	  the	  five	  dilution	  series.	  100	  uL	  of	  the	  10-­‐1	  dilution	  was	  mixed	  with	  900	  uL	  of	  90%	  methanol,	  vortexed	  and	  was	  labeled	  as	  the	  100-­‐fold	  dilution	  (10-­‐2).	  This	  process	  was	  repeated	  until	  the	  10-­‐5	  dilution	  was	  created	  for	  each	  extraction.	  
MTT Assay Cells	  were	  counted,	  trypsinised	  and	  plated	  in	  96	  well	  plates	  at	  a	  concentration	  of	  1x10^4	  cells	  per	  well	  in	  100ul	  of	  media	  (DMEM+10%	  FBS+1%	  PenStrep+1%	  Glutamine).	  Cells	  were	  given	  24	  hours	  to	  adhere	  before	  	  media	  was	  aspirated	  and	  replaced	  with	  80ul	  of	  Phenol-­‐Red	  free	  DMEM	  +	  5%	  Charcoal	  Stripped	  FBS	  +	  1%	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PenStrep	  +	  1%	  Glutamine	  (Phred-­‐Free).	  After	  24	  hours	  an	  additional	  20ul	  of	  Phred-­‐free	  media	  mixed	  with	  1uL	  of	  desired	  supplement.	  After	  48	  hours	  20uL	  of	  CellTiter	  96	  Aqueous	  One	  solution	  (manufactured	  by	  Promega)	  was	  added	  to	  each	  well,	  incubated	  for	  2-­‐4	  hours,	  and	  absorbance	  was	  	  read	  using	  a	  	  	  plate	  reader	  at	  570nm.	  
 
Cell Synchronization For	  some	  experiments	  as	  noted	  in	  results,	  	  cells	  were	  synchronized	  to	  the	  same	  point	  of	  the	  cell	  cycle.	  After	  24	  hours	  of	  adhesion	  in	  the	  96	  well	  plates,	  the	  original	  	  media	  was	  replaced	  with	  100uL	  of	  	  media	  without	  serum	  (	  DMEM+	  1%	  PenStrep+	  1%	  glutamine).	  After	  24	  hours	  this	  media	  was	  aspirated,	  and	  replaced	  immediately	  with	  100uL	  of	  Phred-­‐free	  media	  containing	  1uL	  of	  the	  desired	  supplement.	  The	  rest	  of	  the	  protocol	  followed	  the	  normal	  MTT	  protocol	  listed	  above. 
Trypsinization For	  some	  experiments,	  as	  indicated	  in	  Results,	  to	  avoid	  inconsistencies	  in	  plating	  due	  to	  cell-­‐to-­‐cell	  adhesion,	  three	  T75	  flasks	  were	  trypsinised	  daily	  for	  a	  5-­‐day	  period	  before	  cell	  counts	  began	  for	  MTT	  plating.	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Results In	  order	  to	  determine	  the	  effects	  of	  the	  supplements	  and	  B-­‐estradiol	  on	  proliferation	  a	  series	  of	  different	  MTT	  assays	  were	  performed.	  These	  included	  a	  series	  of	  serial	  dilution,	  time-­‐based,	  B-­‐estradiol	  concentration,	  and	  stock	  treatments	  on	  the	  T47D-­‐Kbluc	  line.	  To	  determine	  the	  makeup	  of	  each	  supplement,	  HPLC	  was	  used	  to	  analyze	  what	  known	  and	  unknown	  components	  were	  present.	  These	  results	  were	  compared	  with	  the	  determined	  effect	  on	  proliferation	  to	  base	  conclusions	  on	  how	  different	  components	  effect	  growth	  within	  the	  cell	  line.	  
Effects on Proliferation An	  initial	  concentration	  curve	  for	  each	  extract	  was	  run	  using	  the	  dilution	  series	  as	  described	  in	  Methods	  to	  determine	  the	  optimal	  concentration	  to	  use	  in	  future	  assays.	  This	  assay	  consisted	  of	  all	  supplements	  and	  controls	  on	  one	  plate.	  The	  supplements	  and	  controls	  underwent	  serial	  dilutions	  to	  see	  the	  effects	  of	  differing	  concentrations	  on	  the	  cells.	  Concentrations	  that	  gave	  the	  best	  results	  would	  be	  used	  in	  the	  future	  assays.	  As	  seen	  in	  Figure	  1,	  however,	  no	  conclusive	  results	  were	  derived	  from	  the	  assay.	  Figure	  one	  shows	  an	  example	  of	  a	  representative	  assay	  using	  the	  original	  MTT	  assay	  method.	  	  
	  
Figure	  1:	  MTT	  Assay,	  Serial	  Dilutions	  of	  Red	  Clover	  Extracts:	  RC	  is	  the	  team-­‐made	  red	  
clover	  extract,	  RCC	  is	  the	  store-­‐bought	  red	  clover	  capsule,	  RCE	  is	  the	  store-­‐bought	  red	  
clover	  extract,	  and	  Prom	  is	  the	  red	  clover	  based	  Promensil.	  The	  plate	  showed	  too	  much	  
variability	  and	  no	  conclusions	  could	  be	  drawn	  from	  the	  dose	  response.	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There	  did	  not	  appear	  to	  be	  an	  effect	  on	  proliferation	  from	  any	  tested	  dilutions	  of	  treatments.	  There	  was	  a	  high	  amount	  of	  variability	  between	  the	  assays	  performed.	  There	  did	  not	  appear	  to	  be	  dose	  dependent	  reactions	  in	  any	  of	  the	  assays.	  	  
	  Next,	  a	  time-­‐based	  assay	  was	  performed	  to	  determine	  the	  ideal	  amount	  of	  time	  to	  run	  future	  assays.	  This	  was	  done	  by	  running	  the	  stock	  solutions	  of	  both	  the	  supplements	  and	  controls	  on	  one	  plate	  and	  leaving	  the	  additions	  on	  the	  cells	  for	  24,	  48,	  and	  72	  hours	  to	  see	  which	  period	  of	  time	  yielded	  the	  cleanest	  results.	  These	  assay	  too,	  however,	  had	  a	  high	  amount	  of	  variability	  on	  the	  plates	  and	  had	  no	  conclusive	  results.	  	  
 
	   	  
Figure	  2:	  MTT	  Assay,	  Red	  Clover	  Extracts	  and	  Controls	  over	  time.	  The	  Red	  clover	  
supplements	  and	  B-­‐estradiol	  had	  increasing	  trends	  while	  the	  media	  and	  methanol	  
controls	  had	  decreasing	  trends.	  However,	  the	  variability	  was	  too	  high	  on	  the	  plate	  to	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Table	  1:	  Raw	  data	  for	  time-­‐based	  MTT	  Assay.	  ST	  is	  the	  soy	  tablet,	  RC	  is	  the	  team-­‐made	  
red	  clover	  extract,	  SC	  is	  the	  soy	  capsule	  ,Prom	  is	  Promensil,	  and	  RCC	  is	  the	  red	  clover	  
capsule.	  **	  indicate	  an	  error	  in	  filling	  the	  wells,	  these	  values	  were	  not	  used	  in	  the	  
averages	  to	  produce	  the	  graphs	  in	  Fig.	  2.	  
	  	   Time	  (Hours)	  
	  	   72 72 72 48 48 48 24 24 24 
media 0.111 0.094 0.095 0.127 0.143 0.188 0.08 0.093 0.097 
meth 0.104 0.157 0.095 0.09 0.089 0.17 0.063 0.098 0.078 
ST 0.084 0.105 0.102 0.086 0.079 0.172 0.098 0.08 0.078 
RC 0.099 0.125 0.105 0.091 0.119 0.193 0.124 0.114 0.12 
SC 0.063 0.078 0.079 0.083 0.113 0.105 0.076 0.073 0.079 
Prom 0.07 0.073 0.076 0.077 0.074 0.081 0.072 0.093** 0.103 
RCC 0.079 0.081 0.096 0.1 0.086 0.137 0.105 0.094 0.112 
B-
estradiol 0.102 0.076 0.082 0.083 0.094 0.094 0.08 0.076** 0.264 	  	  Inconsistencies	  with	  the	  above	  results	  led	  to	  us	  modifying	  the	  protocol	  to	  include	  a	  period	  of	  serum	  starving	  the	  cells	  to	  synchronize	  them	  in	  G0	  before	  stimulating	  proliferation.	  .	  The	  first	  assay	  with	  this	  new	  protocol	  was	  a	  test	  of	  four	  different	  B-­‐estradiol	  concentrations	  to	  determine	  if	  the	  T47D-­‐Kbluc	  line	  to	  determine	  whether	  we	  could	  demonstrate	  estrogen	  responsiveness.	  .	  B-­‐estradiol	  concentrations	  tested	  included	  1x10-­‐8M,	  1x10-­‐9M,	  1x10-­‐10M,	  and	  1x10-­‐11M.	  after	  48	  hours	  of	  exposure	  the	  plate	  was	  read	  at	  570nm.	  
	   
	  
Figure	  3:	  B-­‐estradiol	  only	  MTT	  assay.	  While	  there	  was	  a	  increasing	  trend	  in	  absorbance	  
as	  the	  concentration	  of	  estradiol	  decreased,	  the	  variability	  on	  the	  plate	  and	  the	  error	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Error	  bars	  represent	  the	  standard	  deviation	  among	  the	  six	  wells	  at	  each	  concentration,	  a	  measure	  of	  intra	  assay	  variability.	  While	  this	  level	  of	  variability	  makes	  any	  analysis	  of	  these	  data	  impossible,	  there	  certainly	  is	  no	  clear	  effect	  on	  proliferation.	  	  	  Because	  of	  continuous	  issues	  with	  variability	  and	  based	  on	  our	  observations	  that	  the	  cells	  tended	  to	  form	  tight	  cell-­‐to-­‐	  adhesion	  which	  resulted	  in	  difficulty	  in	  obtaining	  a	  single	  cell	  suspension	  for	  plating,	  we	  decided	  to	  trypsinize	  the	  cells	  daily	  for	  a	  week	  prior	  to	  plating	  in	  96	  well	  plates	  in	  an	  attempt	  to	  avoid	  cellular	  clumping.	  	  	  Finally,	  two	  identical	  assays	  were	  run	  testing	  the	  four	  B-­‐estradiol	  concentrations,	  undiluted	  stock	  solutions	  for	  store-­‐bought	  red	  clover	  extract,	  red	  clover	  capsule,	  Promensil,	  the	  team-­‐made	  red	  clover	  extract,	  media	  control,	  and	  methanol	  control.	  	  
 
 
Figure	  4:	  MTT	  Assay	  post-­‐incubation.	  The	  first	  four	  columns	  labeled	  “-­‐8-­‐‘11”	  contain	  
1x10-­‐8M,	  1x10-­‐9M,	  1x10-­‐10M,	  and	  1x10-­‐11M	  B-­‐estradiol.	  RCE	  is	  the	  store	  bought	  red	  
clover	  extract,	  RCC	  is	  the	  red	  clover	  capsule,	  Prom	  is	  Promensil,	  RC	  is	  the	  team-­‐made	  red	  
clover	  extract,	  med	  is	  media	  control,	  and	  meth	  is	  the	  methanol	  control.	  The	  two	  boxed	  
wells	  on	  plate	  2	  were	  to	  indicate	  potential	  plating	  error.	  	  The	  color	  variation	  between	  columns	  indicates	  the	  difference	  in	  proliferation.	  Darker	  color	  indicates	  higher	  proliferation.	  Lighter	  color	  indicates	  little	  or	  no	  proliferation.	  The	  assay	  shown	  in	  Figure	  4,	  unlike	  previously	  run	  assays,	  showed	  noticeable	  differences	  in	  proliferation	  by	  eye	  before	  quantifying	  the	  data	  with	  absorbance	  values.	  The	  columns	  containing	  B-­‐estradiol	  as	  previously	  found	  experienced	  little	  proliferation,	  and	  high	  variability	  between	  wells.	  	  	  The	  supplements	  appear	  to	  be	  less	  variable	  by	  eye.	  The	  store-­‐bought	  red	  clover	  extract	  showed	  the	  highest	  proliferation,	  while	  Promensil	  does	  not	  appear	  to	  have	  experienced	  any	  when	  compared	  to	  the	  media	  or	  methanol	  controls.	  The	  red	  clover	  capsule	  and	  team-­‐made	  red	  clover	  extract	  also	  increased	  proliferation.	  	  
	   21	  
Absorbance	  values	  were	  as	  a	  result	  more	  indicative	  of	  trends	  than	  in	  the	  previously	  run	  assays.	  Table	  2	  and	  3	  below	  show	  the	  raw	  absorbance	  data	  for	  plate	  1	  and	  plate	  2.	  As	  before	  these	  were	  read	  at	  570nm	  after	  incubation	  with	  titer	  for	  2-­‐4	  hours.	  	  
Table	  2:	  Raw	  data	  for	  final	  MTT	  assay,	  plate	  1.	  RCE	  is	  the	  store-­‐bought	  red	  clover	  
extract,	  RCC	  is	  the	  red	  clover	  capsule,	  prom	  is	  Promensil,	  RC	  is	  the	  team-­‐made	  red	  
clover	  extract,	  med	  is	  media,	  and	  meth	  is	  methanol.	  **	  indicate	  potential	  outliers	  that	  




Plate	  1	   B-estradiol Supplements Control 








11 M RCE RCC Prom RC Med Meth 
A 1.646** 1.195** 0.793 1.524** 2.136 1.531 0.197 0.177** 0.798 0.842 
B 0.772 0.577 0.673 0.413 1.118 1.535 0.377 1.889 1.005** 0.876 
C 0.635 2.111** 0.586 0.767 2.208 1.698 0.176 2.054 0.75 0.428 
D 0.512 0.492 0.804 0.568 1.687 1.68 0.309 1.978 0.759 0.975 
E 0.508 0.345 0.737 0.491 1.996 0.65 0.287 1.62 0.552 0.417 
F 0.369 0.408 0.376 0.175 1.983 1.527 0.187 1.59 0.328 0.374 
G 0.279 0.265 0.306 0.112 1.559 0.668 0.145 1.465 0.284 0.138 	  Table	  2	  showed	  more	  variation	  in	  data,	  there	  were	  six	  wells	  that	  had	  values	  well	  out	  of	  the	  range	  of	  other	  wells	  in	  the	  same	  treatment	  group.	  These	  varied	  values	  are	  potentially	  due	  to	  error	  and	  are	  indicated	  with	  **	  in	  the	  table.	  	  As	  in	  the	  image	  of	  this	  plate	  shown	  in	  Figure	  4,	  the	  store	  bought	  red	  clover	  extract	  showed	  the	  most	  effect	  on	  proliferation	  with	  the	  highest	  overall	  absorbance	  units	  on	  the	  plate.	  	  
Table	  3:	  Raw	  data	  for	  final	  MTT	  assay,	  plate	  2.	  RCE	  is	  the	  store-­‐bought	  red	  clover	  
extract,	  RCC	  is	  the	  red	  clover	  capsule,	  prom	  is	  Promensil,	  RC	  is	  the	  team-­‐made	  red	  
clover	  extract,	  med	  is	  media,	  and	  meth	  is	  methanol.	  **	  indicate	  potential	  outliers	  that	  




Plate	  2	   B-estradiol Supplements Control 
	  	   -8 -9 -10 -11 RCE RCC Prom RC Med Meth 
A 0.549 0.408 0.356 0.189 2.464 0.599 0.54 0.803 0.419 0.281 
B 0.544 0.379 0.526 0.298 2.031 1.17 0.385 0.996 0.576 0.286 
C 0.744 0.567 0.575 0.744** 2.335 1.038 0.371 2.14** 0.502 0.613 
D 0.61 0.634 0.563 0.368 2.611 0.361** 0.205 1.188 0.567 0.275 
E 0.504 0.617 0.514 0.102 2.378 1.397 0.374 1.522 0.342 0.118 
F 0.658 1.849** 0.549 0.352 2.302 1.045 0.493 1.806 0.233 0.56 
G 0.598 0.537 0.431 0.428 2.052 1.265 0.372 1.221 0.371 0.251 	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Table	  3	  shows	  less	  variation	  than	  table	  2.	  There	  are	  4	  wells	  that	  had	  values	  well	  out	  of	  the	  range	  of	  other	  wells	  in	  the	  same	  treatment	  group.	  These	  varied	  values	  are	  potentially	  due	  to	  error	  and	  are	  indicated	  with	  **	  in	  the	  table.	  As	  in	  the	  image	  of	  this	  plate	  shown	  in	  Figure	  4,	  the	  store-­‐bought	  red	  clover	  extract	  showed	  the	  most	  effect	  on	  proliferation.	  The	  store-­‐bought	  red	  clover	  extract	  group	  on	  plate	  two	  also	  had	  higher	  absorbance	  values	  than	  the	  same	  group	  on	  plate	  one.	  	  The	  absorbance	  values	  for	  each	  treatment	  group	  on	  a	  single	  plate	  were	  averaged	  together,	  and	  standard	  deviation	  was	  calculated	  to	  produce	  the	  graphical	  representations	  shown	  in	  Figures	  5	  and	  6.	  Figure	  5	  shows	  the	  results	  for	  the	  B-­‐estradiol	  treatments.	  
 
	    

















B-­‐estradiol	  Dilutions	  MTT	  
Assay	  Plate	  1	  
















B-­‐estradiol	  Dilutions	  MTT	  
Assay	  Plate	  2	  
1x10^-­‐8M	  1x10^-­‐9M	  1x10^-­‐10M	  1x10^-­‐11M	  Media	  Methanol	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Figure	  6:	  MTT	  Assay,	  Red	  Clover	  Supplements	  and	  Controls	  for	  plates	  1	  and	  2,	  RCE	  is	  the	  
store-­‐bought	  red	  clover	  extract,	  RCC	  is	  the	  red	  clover	  capsule,	  RC	  is	  the	  team-­‐made	  red	  
clover	  extract.	  	  The	  store-­‐bought	  red	  clover	  extract	  showed	  the	  largest	  increase	  in	  proliferation.	  The	  red	  clover	  capsule,	  and	  the	  team-­‐made	  red	  clover	  extract	  also	  showed	  an	  increase	  in	  proliferation.	  Promensil	  appears	  to	  have	  no	  effect	  on	  cell	  proliferation.	  	  	  
 
	  
Figure	  7:	  MTT	  Assay	  Comparison	  of	  Store	  Bought	  Red	  Clover	  Extract	  and	  Promensil	  with	  
respect	  to	  media	  and	  methanol	  controls.	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HPLC High	  performance	  liquid	  chromatography	  (HPLC)	  was	  used	  to	  confirm	  the	  presence	  of	  known	  phytoestrogens	  (diadzein,	  genestein,	  and	  biochannin	  A)	  in	  the	  OTC	  phytoestrogen	  supplements	  using	  known	  phytoestrogen	  standards.	  The	  data	  collected	  from	  performing	  HPLC	  on	  the	  supplements	  was	  examined	  to	  see	  if	  any	  of	  the	  supplement	  components	  matched	  with	  the	  known	  standard	  components.	  Figure	  8,	  shown	  below,	  is	  the	  HPLC	  run	  for	  the	  phytoestrogen	  standard	  daidzein.	  	  	  
 
Figure	  8:	  HPLC	  profile	  of	  Daidzein	  	  Figure	  8	  shows	  that	  daidzein	  had	  a	  component	  with	  the	  peak	  elution	  time	  of	  19.98	  minutes	  and	  comprises	  98.43%	  of	  the	  total	  area	  of	  the	  daidzein	  trace.	  Figure	  9,	  shown	  below,	  is	  the	  HPLC	  run	  for	  the	  phytoestrogen	  standard	  genistein.	  	  
 
Figure	  9:	  HPLC	  profile	  of	  Genistein	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Figure	  9	  shows,	  the	  most	  prominent	  peak	  for	  genistein	  is	  found	  at	  22.58	  minutes	  and	  comprises	  98.5%	  of	  the	  trace	  area.	  Figure	  10,	  shown	  below,	  is	  the	  HPLC	  run	  for	  the	  final	  phytoestrogen	  standard	  biochanin	  A.	  	  
 
Figure	  10:	  HPLC	  profile	  of	  Biochanin	  A 
 As	  seen	  in	  Figure	  10,	  the	  trace	  showed	  two	  prominent	  elution	  peaks,	  one	  at	  27.37	  minutes	  that	  comprised	  51.86%	  of	  the	  total	  trace	  area,	  and	  another	  at	  27.48	  that	  comprised	  43.00%	  of	  the	  total	  trace	  area.	  As	  the	  elution	  peaks	  are	  so	  close	  and	  other	  runs	  showed	  the	  two	  elutions	  as	  a	  single	  elution,	  this	  peaks	  likely	  represent	  one	  component.	  Figure	  11	  shown	  below,	  is	  the	  HPLC	  run	  of	  the	  store-­‐bought	  red	  clover	  extract.	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(3.82%	  of	  total	  trace	  area),	  and	  biochanin	  A	  (19.81%	  of	  total	  trace	  area).	  Figure	  12	  shown	  below,	  is	  the	  HPLC	  run	  of	  the	  team-­‐made	  red	  clover	  plant	  extract.  
 
 
Figure	  12:	  HPLC	  profile	  of	  the	  team-­‐made	  red	  clover	  plant	  extract	  	  As	  shown	  in	  Figure	  12,	  the	  plant	  extract	  contained	  components	  with	  peak	  elution	  times	  of	  22.75	  minutes	  (0.064%	  of	  total	  trace	  area),	  and	  27.58	  minutes	  (0.63%	  of	  total	  trace	  area),	  showing	  that	  there	  are	  likely	  traces	  of	  the	  phytoestrogen	  standards	  in	  the	  plant	  extract.	  Figure	  13,	  shown	  below,	  is	  the	  HPLC	  run	  for	  the	  Promensil	  supplement.	  	  
 
Figure	  13:	  HPLC	  profile	  of	  Promensil 
 As	  shown	  in	  Figure	  13,	  the	  Promensil	  contained	  components	  with	  peak	  elution	  times	  of	  24.437	  minutes	  (36.3757%	  of	  total	  trace	  area),	  and	  27.584	  minutes	  (48.8476%	  of	  total	  trace	  area).	  Figure	  14,	  shown	  below	  is	  the	  HPLC	  run	  of	  the	  Red	  Clover	  Capsule.	  	  
 
Genistein	   Biochanin	  A	  
Biochanin	  A	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Figure	  14:	  HPLC	  profile	  of	  the	  red	  clover	  capsules 
 As	  shown	  in	  Figure	  14,	  the	  red	  clover	  capsule	  contained	  components	  with	  peak	  elution	  times	  of	  18.888	  minutes	  (10.4639%	  of	  total	  trace	  area),	  19.137	  minutes	  (16.1240%	  total	  trace	  area),	  and	  21.508	  minutes	  (25.2635%	  of	  total	  trace	  area).	  Figure	  15,	  shown	  below	  is	  the	  HPLC	  run	  for	  the	  soy	  capsule	  supplement.	  	  
 
 
Figure	  15:	  HPLC	  profile	  of	  Piping	  Rock	  Soy	  Isoflavone	  capsules 
 As	  shown	  in	  Figure	  15,	  the	  Soy	  Capsule	  contained	  components	  with	  peak	  elution	  times	  of	  15.365	  minutes	  (21.4738%	  of	  total	  trace	  area),	  15.028	  minutes	  (14.7738%	  total	  trace	  area),	  and	  18.462	  minutes	  (19.9833%	  of	  total	  trace	  area	  	  Figure	  16,	  show	  below,	  is	  the	  HPLC	  data	  for	  the	  Spring	  Valley	  tablet.	  	  	  
Genistein	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Figure	  16:	  HPLC	  profile	  of	  Spring	  Valley	  Soy	  Isoflavone	  tablets 
 As	  shown	  in	  Figure	  16,	  the	  Soy	  Valley	  Tablet	  contained	  components	  with	  peak	  elution	  times	  of	  15.009	  minutes	  (22.1919%	  of	  total	  trace	  area),	  16.870	  minutes	  (33.1452%	  of	  total	  trace	  area),	  and	  17.186	  minutes	  (22.0611%	  of	  total	  trace	  area).	  Other	  notable	  components	  were	  found	  at	  peak	  elution	  times	  of	  15.358	  minutes	  (6.6485%	  of	  total	  trace	  area)	  and	  15.395	  minutes	  (5.9622%).	  	  	  Other	  notable	  peaks	  for	  each	  tested	  supplement	  are	  summarized	  in	  table	  4.	  Each	  peak	  is	  described	  by	  elution	  time	  in	  minutes,	  and	  by	  %	  of	  total	  trace	  area.	  
Table	  4:	  Additional	  Notable	  Peaks	  by	  Supplement	  



































3.8	   3.56	   3.69	   45.69	   16.876	   9.2918	   16.874	   7.1059	   15.538	   6.6485	  
14.46	   6.39	   16.84	   4.49	   20.852	   5.8238	   17.192	   8.9611	   15.395	   5.9622	  
16.78	   14	   17.36	   1.96	   	  	   	  	   20.424	   8.8716	   	  	   	  	  
19.11	   2.76	   20.91	   5.67	   	  	   	  	   	  	   	  	   	  	   	  	  
20.88	   3.74	   21.51	   0.81	   	  	   	  	   	  	   	  	   	  	   	  	  
21.51	   2.76	   24.51	   0.23	   	  	   	  	   	  	   	  	   	  	   	  	  
22.09	   2.67	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
23.31	   2.12	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
24.44	   8.95	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
26.2	   1.08	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Table	  5,	  shown	  below,	  was	  created	  to	  show	  which	  supplements	  shared	  components	  with	  the	  standards	  and	  also	  the	  components	  that	  were	  shared	  amongst	  the	  supplements	  being	  tested.	  	  	  
 









Do	  cells	  proliferate	  in	  supplement's	  
presence? 
Yes Yes Yes No 





Genistein X X 
 
 
Biochanin	  A X X  X 
Shared	  unidentified	  peaks	  
(Retention	  time	  in	  minutes) 
    
3.66 X X X 
 
16.87 X X X X 
20.53 X X X X 
21.51 X X X X 
24.34 X X X X 
27.58 X X X X 
Other	  notable	  peaks	  (Retention	  
time	  in	  minutes) 
14.46,	  19.11,	  22.06,	  
23.31,	  and	  26.20 
17.35 14.46,	  and	  
14.98 
23.31	  and	  
26.20 	  Table	  4	  gives	  a	  summary	  of	  all	  chromatograms	  for	  the	  tested	  red	  clover	  supplements	  and	  compares	  the	  presence	  of	  both	  known	  and	  unknown	  components.	  Biochanin	  A	  is	  found	  in	  three	  of	  the	  four	  supplements,	  while	  daidzein	  and	  genestine	  are	  found	  in	  two	  each.	  Both	  the	  red	  clover	  capsules	  and	  Promensil	  only	  contain	  one	  known	  component.	  All	  components	  share	  unidentified	  peaks.	  
Discussion Based	  on	  both	  the	  MTT,	  and	  HPLC	  results,	  we	  came	  to	  the	  following	  conclusions	  regarding	  the	  effects	  of	  these	  dietary	  supplements	  on	  breast	  cancer.	  Across	  all	  tested	  red	  clover	  supplements,	  there	  was	  variation	  in	  which	  known	  components	  were	  present.	  Three	  tested	  supplements,	  store-­‐bought	  red	  clover	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extract,	  team-­‐made	  red	  clover	  extract,	  and	  red	  clover	  capsules	  shared	  six	  unidentified	  peaks,	  while	  Promensil	  only	  shared	  five	  peaks	  in	  common.	  	  The	  supplement	  that	  caused	  the	  largest	  increase	  in	  proliferation	  according	  to	  MTT	  assay	  was	  the	  store-­‐bought	  red	  clover	  extract.	  In	  addition	  to	  having	  the	  largest	  impact	  on	  proliferation,	  it	  had	  the	  largest	  number	  of	  peaks	  on	  its	  HPLC.	  The	  extract	  contained	  all	  three	  known	  phytoestrogen	  components	  tested	  for,	  diadzen,	  genestein,	  and	  biochannin	  A,	  six	  unknown	  peaks	  in	  common	  with	  other	  tested	  supplements,	  and	  six	  further	  notable	  unknown	  peaks	  that	  it	  does	  not	  share	  with	  other	  tested	  supplements.	  Of	  these	  peaks	  the	  peak	  of	  greatest	  interest	  is	  the	  peak	  found	  at	  24.34	  minutes,	  which	  is	  found	  in	  all	  tested	  red	  clover	  supplements,	  as	  well	  as	  some	  tested	  soy	  supplements.	  	  	  Biochannin	  A,	  the	  only	  standard	  found	  in	  Promensil,	  is	  known	  to	  have	  anti-­‐proliferative	  effects	  (Johnson,	  2010).	  This	  is	  supportive	  of	  the	  idea	  that	  Promensil	  can	  be	  used	  to	  ease	  symptoms	  of	  menopause	  with	  less	  fear	  of	  the	  potentially	  harmful	  effects	  of	  traditional	  hormone	  replacement	  therapy	  (HRT).	  	  Both	  extracts	  (store-­‐bought	  and	  team-­‐made)	  contained	  biochannin	  A,	  however	  the	  store-­‐bought	  extract	  also	  contained	  genestein	  and	  daidzen,	  while	  the	  team-­‐made	  extract	  contained	  genestine	  but	  no	  daidzen.	  This	  suggests	  that	  because	  both	  extracts	  saw	  an	  increase	  in	  proliferation,	  that	  diadzen	  and	  genestein	  both	  have	  proliferative	  effects.	  It	  is	  unclear	  whether	  the	  presence	  of	  both	  causes	  a	  sort	  of	  multiplied	  effect.	  	  	  Future	  teams	  should	  test	  standards,	  alone	  and	  in	  combination	  to	  see	  what	  the	  effects	  isoflavones	  have	  on	  proliferation	  without	  the	  outside	  factors	  present	  in	  testing	  manufactured	  supplements,	  which	  do	  not	  contain	  pure	  phytoestrogens.	  	  The	  most	  surprising	  trend	  observed	  in	  the	  results	  was	  the	  difference	  between	  the	  store-­‐bought	  red	  clover	  extract,	  and	  the	  team-­‐made	  red	  clover	  extract.	  At	  face-­‐value	  these	  two	  extracts	  were	  the	  most	  similar	  treatments	  used	  in	  our	  experiments	  as	  they	  were	  (according	  to	  the	  label)	  both	  made	  from	  red	  clover	  flowers	  and	  leaves,	  and	  extracted	  in	  alcohol.	  The	  store-­‐bought	  extract	  had	  minimal	  information	  on	  the	  label	  regarding	  ingredients,	  and	  is	  taken	  orally.	  We	  also	  have	  no	  information	  on	  what	  point	  within	  the	  plant’s	  life	  cycle	  flowers	  and	  leaves	  were	  harvested	  during	  or	  where	  the	  plants	  were	  grown.	  For	  our	  own	  extract	  the	  red	  clover	  plants	  were	  a	  wild	  cultivar	  grown	  in	  Massachusetts.	  	  	  In	  the	  future	  a	  way	  to	  explore	  the	  effects	  of	  the	  potentially	  very	  different	  ages	  of	  the	  plant,	  and	  cultivars,	  teams	  can	  extract	  red	  clover	  from	  a	  variety	  of	  points	  in	  the	  season	  in	  one	  area.	  Additionally	  testing	  wild	  cultivars	  versus	  greenhouse,	  or	  genetically	  modified	  cultivars	  could	  provide	  more	  answers	  as	  to	  why	  there	  may	  have	  been	  differences	  in	  the	  isoflavones	  present	  between	  the	  two	  extracts	  tested	  in	  this	  study.	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Limitations of the study Our	  study	  had	  some	  impactful	  limitations.	  Due	  to	  difficulties	  in	  acquiring	  meaningful	  data,	  the	  sample	  size	  of	  our	  final	  assay	  is	  very	  small	  (N=2).	  	  We	  were	  also	  unable	  to	  identify	  any	  proliferative	  effects	  in	  our	  cell	  line	  in	  response	  to	  B-­‐estradiol.	  This	  was	  likely	  due	  to	  high	  variance	  in	  cell	  number	  between	  wells	  despite	  cell	  counting.	  Our	  cell	  line	  experienced	  issues	  with	  extreme	  cell-­‐to-­‐cell	  adhesion,	  which	  made	  consistency	  while	  plating	  difficult.	  The	  week-­‐long	  period	  of	  trypsinization	  and	  subsequent	  synchronization	  by	  serum	  starvation	  	  presented	  us	  with	  promising	  results.	  Future	  groups	  should	  consider	  synchronization	  from	  the	  beginning	  of	  the	  experiment	  to	  reduce	  variability.	  	  It	  is	  possible	  that	  other	  factors	  could	  have	  played	  a	  role	  in	  the	  difference	  of	  proliferation	  for	  the	  store-­‐bought	  red	  clover	  extract	  and	  the	  Promensil.	  One	  of	  these	  factors	  is	  a	  possible	  difference	  in	  cell	  number	  between	  the	  wells	  because	  of	  the	  excessive	  clumping.	  While	  the	  trypsinization	  period	  did	  separate	  most	  of	  the	  cells,	  there	  still	  was	  a	  possibility	  of	  continued	  clumping.	  	  	  Future	  groups	  should	  focus	  on	  identifying	  some	  of	  the	  unknown	  peaks	  that	  appear	  within	  more	  than	  one	  supplement,	  like	  the	  one	  at	  24.37	  minutes.	  These	  unknown	  peaks	  could	  be	  the	  reason	  similar	  supplements	  like	  the	  red	  clover	  capsule	  and	  Promensil	  have	  different	  effects	  on	  proliferation.	  	  Known	  and	  unknown	  components	  can	  be	  collected	  and	  added	  to	  the	  cells	  to	  determine	  which,	  if	  any	  have	  proliferative	  or	  anti-­‐proliferative	  effects.	  This	  can	  further	  solidify	  what	  makes	  these	  supplements	  different,	  while	  they	  are	  marketed	  as	  coming	  from	  the	  same	  plant.	  	  After	  these	  components	  have	  been	  identified,	  the	  estrogen	  promoter	  regulated	  reporter	  can	  be	  used	  to	  determine	  which	  estrogen	  receptor	  the	  compound	  is	  interacting	  with,	  which	  can	  give	  more	  insight	  into	  that	  compounds’	  proliferative	  or	  anti-­‐proliferative	  effects.	  Additionally,	  immunoblotting	  can	  determine	  if	  any	  of	  these	  compounds	  rather	  than	  being	  anti-­‐proliferative	  are	  actually	  triggering	  the	  apoptotic	  cascade.	  The	  small	  sample	  size	  of	  our	  results	  leaves	  us	  unable	  to	  say	  anything	  definitively,	  however,	  we	  can	  use	  the	  trends	  presented	  to	  us	  to	  form	  a	  basis	  for	  future	  studies.	  The	  conclusions	  and	  recommendations	  in	  this	  paper	  will	  help	  other	  groups	  to	  shoot	  past	  the	  point	  of	  tentative	  trial	  assays,	  and	  delve	  deeper	  into	  learning	  more	  about	  the	  effects	  of	  these	  components	  on	  breast	  cancer.	  This	  is	  a	  problem	  that	  must	  continue	  to	  be	  explored	  to	  allow	  the	  public	  to	  make	  informed	  decisions	  about	  the	  safety	  of	  these	  unregulated	  supplements,	  and	  take	  greater	  responsibility	  in	  their	  healthcare.	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